Skip to main content

Table 2 Designs of the identified studies evaluating restriction policies for pregabalin

From: A systematic review of the effectiveness of policies restricting access to pregabalin

  Margolis et al., 2009 [27] Margolis, et al., 2010 [28] Bazalo et al., 2010 [26] Udall et al., 2014 [30] Suehs et al., 2014 [31] Placzek et al., 2014 [29] Null et al., 2016 [32] Martin et al., 2016 [33]
Study design (population) Retrospective database (Medicaid) Retrospective database (commercial) Modeling (IMS prescription data) Retrospective database (commercial) Retrospective database (Medicare) Retrospective database (commercial) Retrospective database (Medicare & commercial) Retrospective database (commercial)
Number of patients Restricted, n = 424; unrestricted, n = 5153 Restricted, n = 2084; unrestricted, n = 1320 Not applicable Restricted, n = 3876; unrestricted, n = 3876 Restricted, n = 13,911; unrestricted, n = 13,911 Restricted, n = 29,283; unrestricted, n = 463 Not applicable Restricted, n = 1218; unrestricted, n = 1218
Restriction type PA PA PA ST ST PA ST Mail order requirement
Conditions evaluated PHN; pDPN PHN; pDPN PHN; pDPN; FM; partial-onset seizures PHN; pDPN; FM PHN; pDPN pDPN; FM pDPN; FM; PHN PHN; pDPN; FM; partial-onset seizures
  1. Abbreviations: FM fibromyalgia, PA prior authorization, pDPN painful diabetic peripheral neuropathy, PHN postherpetic neuralgia, ST step therapy